4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzyl)piperidine-1-carboxylic acid

This compound is an experimental small molecule known as PF‑3845, primarily recognized as a potent and selective inhibitor of fatty acid amide hydrolase (FAAH), an enzyme responsible for the degradation of endocannabinoids such as anandamide. By inhibiting FAAH, this molecule increases levels of endogenous cannabinoids, which may have implications in pain management, inflammation, and neurological disorders. It has not been approved for clinical use and remains at the experimental or preclinical stage. The compound is used mainly in research settings to study endocannabinoid signaling pathways and their physiological effects.[1][3]

Other names

4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzyl)piperidine-1-carboxylic acidN-(Pyridin-3-yl)-4-(3-{[5-(trifluoromethyl)-2-pyridinyl]oxy}benzyl)-1-piperidinecarboxamideN-pyridin-3-yl-4-[3-[5-(trifluoromethyl)pyridin‑2‑yl]oxyphenyl]methylpiperidine‑1‑carboxamide